The Boule Diagnostics board has resolved to revise the company’s financial targets and to adjust the dividend policy.
The financial targets that will apply effective today are:
- An operating margin (EBIT-margin) above 15 percent.
- Long term growth in sales above 10 percent per year.
- Net debt (interest bearing debts minus cash and cash equivalents) no greater than three times operating profit (EBIT) on an annualized basis.
The board has also resolved to adjust the dividend policy.
- The annual dividend should correspond to 25-50 percent of profit for the period, after taking due consideration to company liquidity.
For more information, please contact:
Ernst Westman, CEO and president, Boule Diagnostics AB, tel +46 708-60 88 63
About Boule Diagnostics AB
Boule Diagnostics AB is a fast-growing diagnostics company, developing and manufacturing systems and consumables for hematology diagnostics for the public healthcare providers worldwide. The company is primarily focused on small and medium-sized hospitals, clinics and laboratories in outpatient care as well as other diagnostics companies in both human and veterinary hematology. The group is comprised of operating subsidiaries in Sweden, the US and China. The Boule Diagnostics share is traded on NASDAQ Nordic since 2011. http://www.boule.se
This information is information that Boule Diagnostics AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above, at 17:30 CET on February 15, 2017.